How Alzheimer's Drug Models Miss a Crucial Factor: Patient Death

A new analysis reveals that cost-effectiveness studies of Alzheimer's treatments often fail to account for mortality rates, potentially distorting which therapies appear most valuable. For health systems, insurers, and drugmakers evaluating which treatments to fund or develop, this oversight could lead to poor investment decisions based on incomplete financial projections.

Originaltitel: Effect of mortality in cost-effectiveness modeling of disease-modifying treatment for Alzheimer's disease